View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Crizotinib 250, Non-Small Cell Lung Cancer (ALK+), Second Line
Protocol-ID: 198 V1.1 (Mini), CRIZ250, NSCLC (ALK+), second lineIndication(s)
- Lung Carcinoma, Non-Small Cell (ALK+); ICD-10 C34.-
Links
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. [PMID]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 07.11.2021